Literature DB >> 7934446

The role of tyrosinase in autoimmune vitiligo.

Y H Song1, E Connor, Y Li, B Zorovich, P Balducci, N Maclaren.   

Abstract

Vitiligo is a common depigmenting skin disease, associated with certain autoimmune endocrinopathies, and autoantibodies to several antigens can be found in melanoma cells. We set out to identify the antigens. We examined 26 patients with vitiligo and associated endocrine disease. Of these, 18 patients (77%) and 8 immediate family members had autoantibodies specific for a 69 kDa protein in HTB-70 human melanoma cells that was not seen in control cells. The autoantibody-positive patient sera reacted with recombinant human tyrosinase expressed in Escherichia coli seen by western blots, as did antibodies raised in rabbits against hamster tyrosinase, but not to recombinant tyrosinase-related protein. Not one of 31 normal controls or 8 patients with alopecia or systemic lupus erythematosus had tyrosinase autoantibodies but a small proportion (12%) of 42 patients with autoimmune endocrine disease without a history of vitiligo had them. The results show that tyrosinase, an enzyme important in melanin formation, is a principal autoantigen of autoimmune vitiligo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7934446     DOI: 10.1016/s0140-6736(94)91709-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

1.  Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo.

Authors:  E H Kemp; E A Waterman; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation.

Authors:  Ying Jin; Tracey Ferrara; Katherine Gowan; Cherie Holcomb; Melinda Rastrou; Henry A Erlich; Pamela R Fain; Richard A Spritz
Journal:  J Invest Dermatol       Date:  2012-03-08       Impact factor: 8.551

3.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

4.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

5.  Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models.

Authors:  N Le Fur; W K Silvers; S R Kelsall; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 6.  Hearing loss in vitiligo: current concepts and review.

Authors:  Marrigje Aagje de Jong; Cahtia Adelman; Menachem Gross
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-02-14       Impact factor: 2.503

7.  Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo.

Authors:  S Sanchez-Sosa; M Aguirre-Lombardo; G Jimenez-Brito; A Ruiz-Argüelles
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

8.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

Authors:  D D Chi; R E Merchant; R Rand; A J Conrad; D Garrison; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

Review 9.  Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?

Authors:  C Betterle; F Lazzarotto; F Presotto
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.